Jeito Capital co-leads €75 million Series B financing in SparingVision
Summary
In co-leading this Series B financing, Jeito Capital is demonstrating its commitment to invest significant capital in continuity, throughout the different development stages of a promising biotech company, to build market leaders with accelerated patients access globally, especially in Europe and the United States.Since 2020 and its first round of financing, SparingVision deployed a very coherent and strong build-up strategy to serve its ambition: (i) acquiring GAMUT Therapeutics, a French biotechnology company pioneering a unique gene-independent approach for more advanced patients; (ii) also signing a strategic collaboration with Intellia Therapeutics (NASDAQ: NTLA), a leading clinical-stage genome editing company. Our new investment in SparingVision illustrates perfectly Jeito Capitals mission to build market leaders with global reach to bring ground-breaking therapies to patients with high unmet needs. True to its values and investment thesis, Jeito is committed to accompany the company with significant funding in continuity, to build the best multi-disciplinary and multi-cultural team of research and biotech experts to accelerate its development through targeted acquisitions. The future therapies, SPVN06, SPVN20 and tomorrow SPVN50, could change the lives of millions of patients suffering from Inherited Retinal Diseases and dry Age Macular Degeneration.St\xe9phane Boissel, President, and Chief Executive Officer of SparingVision, said: With this financing, we are taking a significant step towards achieving clinical validation of our two lead assets and bringing mutation-agnostic genomic medicines to millions of patients affected by IRDs and dry AMD. Our ambition does not stop here, and we remain fully concentrated on our three core pillars of exploration: our mutation-agnostic gene therapies, the genome editing technology toolbox of our strategic partner Intellia Therapeutics and the potential of in-vivo reprogramming in the retina.